Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Medacta Group SA    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Medacta : Announces First Hip Replacement Surgeries with New Quadra-P System

06/30/2020 | 03:05pm EST


EQS Group-Media / 30.06.2020 / 21:00

Media Release

Medacta Announces First Hip Replacement Surgeries with New Quadra-P System Following Successful FDA Clearance and CE Marking

CASTEL SAN PIETRO, 30 June 2020 - Medacta announced today the first surgeries in the U.S. and Europe with its new Quadra-P Collared and Quadra-P Cemented femoral stems following recent clearance from the U.S. Food and Drug Administration (FDA) and CE marking in Europe.

These new stem options follow the successful release of Medacta's Quadra-P hip prosthesis in 2019 and together, complete the Quadra-P Hip System, a complete system of stems for use in hip replacement surgery. The first Quadra-P Cemented stem was implanted on March 4, 2020 by Thomas McCoy, M.D., in Leesburg, Florida (U.S.), while the first surgeries utilizing the Quadra-P Collared stem were performed on May 25, 2020 by Dr. Med. Panayiotis Christofilopoulos in Geneva, Switzerland, and May 26, 2020 by Peter Thadani, M.D., in Chicago (U.S.).

Quadra-P is part of the Medacta Family of P-Stems, along with AMIStem-P and SMS. The tapered rectangular stems all feature proximal coating and progressive neck lengths, with a range of stem lengths and canal filling dimensions that give clinicians the ability to match an implant to the patient's bone morphology.

"Stem selection is a critical component to positive patient outcomes, and the P-Stem Family affords our surgeons the ability to select a distally reduced, collarless, collared or cemented stem that best matches their patient's femoral bone morphology and bone quality," said Francesco Siccardi, CEO of Medacta. "With this broader range of innovative stem options, we are able to provide surgeons with an enhanced complete system for total hip arthroplasty that better meets the needs of a wide range of patients."

The Quadra-P System is the evolution of the original Quadra-H System, the first stem Medacta developed, which features a remarkable clinical heritage of more than 15 years, outstanding survival rates (99.6% at 10 years) and thousands of stems implanted worldwide each year.

In alignment with Medacta's mission to transform the patient experience by advancing solutions through responsible innovation, the Quadra-P System has been enhanced with MectaGrip, Medacta's state-of-the-art proximal coating; progressive head center growth that more closely reflects the patient's natural anatomy; and a collared option that further expands the system's offerings.

"Medacta has built upon the excellent long-term results of its fully HA-coated femoral stems by adding a proximal MectaGrip coating to the Quadra-P stem system," said John Masonis, M.D., of OrthoCarolina Hip & Knee Center in Charlotte, North Carolina (U.S.), one of the Quadra-P designers. "The MectaGrip coating allows for more proximal load transfer and provides a mechanically stronger bone-to-implant interface. The single system expands on the proven stability of the cementless Quadra by adding the cementless with collar and updated cemented options. This gives me and other surgeons a stem system that can address different femoral bone morphologies among a varying patient population."

The MectaGrip coating is designed for enhanced initial stability and long-term fixation to satisfy higher demands of younger, more active patients who put more stress on their implants. The anatomical head center growth makes the Quadra-P System particularly suitable to more efficiently restore the native hip joint biomechanics in a larger population.

The Quadra-P System also provides the utmost in intraoperative flexibility as a collarless, collared or cemented stem, as all options use a single instrument platform, potentially increasing operating room efficiency and streamlining processes for surgeons and health systems.

For more information on the Quadra-P System, visit https://www.medacta.com/EN/quadra-p-system-global.

Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch

About Medacta
Medacta is an international company specialized in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques for joint replacement, spine surgery, and sports medicine. Established in 1999 in Switzerland, Medacta's products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS") technique for hip replacements. Medacta has leveraged its orthopaedic expertise and comprehensive understanding of the human body to develop the sophisticated "MySolutions" technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures.



Issuer: Medacta Group SA
Key word(s): Research/Technology

End of Corporate News


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1083057

 
End of News EQS Group Media

1083057  30.06.2020 

fncls.ssp?fn=show_t_gif&application_id=1083057&application_name=news&site_id=zonebourse

© EQS 2020
All news about MEDACTA GROUP SA
11/04MEDACTA : proposes the election of Riccardo Braglia as new independent member of..
EQ
10/19MEDACTA : Expands its Knee Offerings with New SensiTiN System with Low Metal Ion..
EQ
10/13MEDACTA : Launches M.U.S.T. 2.0 Instrumentation to Expand its Offerings for Spin..
EQ
09/29MEDACTA : Expands its Knee Portfolio with 3DMetal Femoral Cones for Knee Revisio..
EQ
09/15MEDACTA : Expands its Partial Knee Replacement Solutions with MOTO Lateral Parti..
EQ
09/07MEDACTA : Publication of 2020 Half Year Results
EQ
09/04MEDACTA : Announces Successful Completion of the First Australian Surgery with N..
EQ
09/02MEDACTA : Receives FDA Clearance for the Lateralized Glenosphere
EQ
07/22MEDACTA : Half-year 2020 revenue equal to Euro 135M, down 11.1% over the prior y..
EQ
07/13MEDACTA TO INTRODUCE NEXTAR(TM) : First FDA-Cleared Augmented Reality-Based Surg..
EQ
More news
Financials
Sales 2020 303 M 358 M 358 M
Net income 2020 31,2 M 36,9 M 36,9 M
Net Debt 2020 114 M 134 M 134 M
P/E ratio 2020 51,4x
Yield 2020 0,52%
Capitalization 1 598 M 1 891 M 1 892 M
EV / Sales 2020 5,66x
EV / Sales 2021 4,68x
Nbr of Employees 1 126
Free-Float 30,7%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 77,35 €
Last Close Price 79,90 €
Spread / Highest target 14,5%
Spread / Average Target -3,19%
Spread / Lowest Target -27,1%
EPS Revisions
Managers
NameTitle
Francesco Siccardi Chief Executive Officer
Alberto Siccardi Executive Chairman
Corrado Farsetta Chief Financial Officer
Maria Luisa Siccardi Tonolli Non-Executive Director
Victor Waldemar Balli Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDACTA GROUP SA19.61%1 901
ABBOTT LABORATORIES27.67%196 537
MEDTRONIC PLC-2.90%148 100
BECTON, DICKINSON AND COMPANY-14.74%67 212
HOYA CORPORATION20.05%45 230
BAXTER INTERNATIONAL INC.-7.89%39 343